uniQure N.V.

Developing AAV gene therapies for severe neurologic and rare genetic diseases, led by AMT-130 in Huntington's disease.

Back to company catalog

Neurology & rare genetic disease · AAV gene therapy · Pivotal Phase 1/2

Compare report options